PDE4D Allosteric Modulators for Treating Cognitive Impairment

描述(申请人提供)：阿尔茨海默病(AD)是由于美国人口老龄化造成的日益严重的医疗负担。阿尔茨海默病是老年人中最常见的痴呆症，它会影响大脑中对记忆形成和恢复至关重要的部分，严重损害一个人独立生活和应对日常活动的能力。与NIH蓝图神经治疗计划合作，我们寻求根据以下目标产品简介开发磷酸二酯酶4型(PDE4)变构调节剂，以改善认知能力。理想情况下，治疗将改善MCI患者的认知，并影响AD的病理生理学，从而减缓向可能的AD的转化。 药物性质最低可接受结果理想结果主要药物适应症轻度认知障碍(MCI)患者认知功能的改善可能是由于从MCI向可能的ADP转化缓慢根据NIAA/AA工作组标准可能由AD引起的MCI患者根据NIAA/AA工作组标准可能由AD引起的MCI患者每日一次口服治疗模式

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is an increasing medical burden due to the aging demographics of the US population. The most common form of dementia among older adults, AD affects parts of the brain important for memory formation and retrieval, seriously impairing a person's ability to live independently and cope with daily activities. In collaboration with the NIH Blueprint Neurotherapeutics Program, we seek to develop phosphodiesterase Type 4 (PDE4) allosteric modulators for improving cognition in accordance with the Target Product Profile below. Ideally, the therapeutic will improve cognition in MCI patients and impact AD pathophysiology, thereby slowing conversion to probable AD. Drug PropertiesMinimum Acceptable ResultIdeal ResultPrimary Drug IndicationImprovement of cognition in persons with Mild Cognitive Impairment (MCI) due to probable ADSlowing of conversion from MCI to probable ADPatient PopulationPatients with MCI due to probable AD according to the NIAA/AA working group criteriaPatients with MCI due to probable AD according to the NIAA/AA working group criteriaDelivery ModeOralOralTreatment DurationChronicChronicRegimenOral, once dailyOral, once daily